Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Author:

Viardot Andreas1,Goebeler Marie-Elisabeth2,Hess Georg3,Neumann Svenja4,Pfreundschuh Michael5,Adrian Nicole5,Zettl Florian6,Libicher Martin7,Sayehli Cyrus2,Stieglmaier Julia8,Zhang Alicia9,Nagorsen Dirk9,Bargou Ralf C.10

Affiliation:

1. Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany;

2. Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany;

3. Department of Hematology, Oncology, and Pneumology, Johannes Gutenberg-University, Mainz, Germany;

4. Medical Department II, University Hospital Schleswig Holstein Campus Kiel, Kiel, Germany;

5. Klinik für Innere Medizin I, Saarland University Medical School, Homburg (Saar), Germany;

6. University Hospital Göttingen, Göttingen, Germany;

7. Department of Radiology, Diakoniekrankenhaus Schwäbisch-Hall, Schwäbisch-Hall, Germany;

8. Amgen Research (Munich), Munich, Germany;

9. Amgen Inc, Thousand Oaks, CA; and

10. Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany

Abstract

Key Points Among evaluable patients with relapsed/refractory DLBCL who received blinatumomab 112 μg/d, overall response was 43% (CR was 19%). Blinatumomab continuous infusion was feasible with weekly stepwise dose escalation (9-28-112 μg/d) and dexamethasone prophylaxis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 278 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3